SCHEMBL1613237

SCHEMBL1613237

CC1(CCCO)C(=O)Nc2cc(Br)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
PIM1 P11309 2/20 0.40
PIM3 Q86V86 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 1/20 0.38
LMNA P02545 2/20 0.37
TP53 P04637 1/20 0.36
CMA1 P23946 1/20 0.36
AHR P35869 1/20 0.36
PNMT P11086 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PKM P14618 1/20 0.34
USP2 O75604 2/20 0.33
F2 P00734 1/20 0.33
CNR1 P21554 1/20 0.33
BRD4 O60885 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31219731 0.91 MEN1 (0.44) MEN1KMT2APIM1PIM3PIM2
SCHEMBL31220147 0.85 MEN1 (0.46) MEN1KMT2APIM1PIM3PIM2
SCHEMBL31220002 0.80 MEN1 (0.44) MEN1KMT2APIM1PIM3PIM2
SCHEMBL1233337 0.76 MAPK14 (0.44) MEN1KMT2APIM1PIM3PIM2
SCHEMBL1613300 0.75 MEN1 (0.40) MEN1KMT2APIM1PIM3PIM2
SCHEMBL12713569 0.75 PIM1 (0.47) MEN1KMT2APIM1PIM3PIM2
SCHEMBL11829 0.73 MEN1 (0.52) MEN1KMT2APIM1PIM3PIM2
SCHEMBL31440532 0.73 MEN1 (0.52) MEN1KMT2APIM1PIM3PIM2
SCHEMBL29502068 0.73 MEN1 (0.52) MEN1KMT2APIM1PIM3PIM2
SCHEMBL31219845 0.73 MEN1 (0.35) MEN1KMT2APIM1PIM3PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2315751-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS Amgen Inc. (US) 2011-05-04 EP disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 WO disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS NFKBIA, MAP3K1, MAP3K2 MEN1 4123/4885KMT2A 2087/4885PIM1 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.